199 related articles for article (PubMed ID: 36524210)
1. Immunological responses to adjuvant vaccination with combined CD1c
Bloemendal M; Bol KF; Boudewijns S; Gorris MAJ; de Wilt JHW; Croockewit SAJ; van Rossum MM; de Goede AL; Petry K; Koornstra RHT; Figdor C; Gerritsen WR; Schreibelt G; de Vries IJM
Oncoimmunology; 2022; 11(1):2015113. PubMed ID: 36524210
[TBL] [Abstract][Full Text] [Related]
2. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
[TBL] [Abstract][Full Text] [Related]
3. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF; Schreibelt G; Bloemendal M; van Willigen WW; Hins-de Bree S; de Goede AL; de Boer AJ; Bos KJH; Duiveman-de Boer T; Olde Nordkamp MAM; van Oorschot TGM; Popelier CJ; Pots JM; Scharenborg NM; van de Rakt MWMM; de Ruiter V; van Meeteren WS; van Rossum MM; Croockewit SJ; Koeneman BJ; Creemers JHA; Wortel IMN; Angerer C; Brüning M; Petry K; Dzionek A; van der Veldt AA; van Grünhagen DJ; Werner JEM; Bonenkamp JJ; Haanen JBAG; Boers-Sonderen MJ; Koornstra RHT; Boomsma MF; Aarntzen EHJ; Gotthardt M; Nagarajah J; de Witte TJM; Figdor CG; de Wilt JHW; Textor J; de Groot JWB; Gerritsen WR; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1632. PubMed ID: 38395969
[TBL] [Abstract][Full Text] [Related]
5. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Schreibelt G; Duiveman-de Boer T; Pots JM; van Oorschot TGM; de Boer AJ; Scharenborg NM; van de Rakt MWMM; Bos K; de Goede AL; Petry K; Brüning M; Angerer C; Schöggl C; Dzionek A; de Vries IJM
Methods Cell Biol; 2024; 183():33-50. PubMed ID: 38548417
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
7. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
9. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
[TBL] [Abstract][Full Text] [Related]
10. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G; Bol KF; Westdorp H; Wimmers F; Aarntzen EH; Duiveman-de Boer T; van de Rakt MW; Scharenborg NM; de Boer AJ; Pots JM; Olde Nordkamp MA; van Oorschot TG; Tel J; Winkels G; Petry K; Blokx WA; van Rossum MM; Welzen ME; Mus RD; Croockewit SA; Koornstra RH; Jacobs JF; Kelderman S; Blank CU; Gerritsen WR; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2016 May; 22(9):2155-66. PubMed ID: 26712687
[TBL] [Abstract][Full Text] [Related]
11. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
12. Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
Tel J; Koornstra R; de Haas N; van Deutekom V; Westdorp H; Boudewijns S; van Erp N; Di Blasio S; Gerritsen W; Figdor CG; de Vries IJ; Hato SV
J Transl Med; 2016 Apr; 14():88. PubMed ID: 27075584
[TBL] [Abstract][Full Text] [Related]
13. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
14. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.
Bloemendal M; Rietveld MJA; van Willigen WW; Gerritsen WR; Figdor CG; Bonenkamp JJ; Westdorp H; Boudewijns S; Koornstra RHT; Adang EMM; Schreibelt G; Ottevanger PB; de Vries IJM; Bol KF
Clin Transl Oncol; 2019 Jun; 21(6):774-780. PubMed ID: 30465182
[TBL] [Abstract][Full Text] [Related]
17. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
18. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S; Bloemendal M; de Haas N; Westdorp H; Bol KF; Schreibelt G; Aarntzen EHJG; Lesterhuis WJ; Gorris MAJ; Croockewit A; van der Woude LL; van Rossum MM; Welzen M; de Goede A; Hato SV; van der Graaf WTA; Punt CJA; Koornstra RHT; Gerritsen WR; Figdor CG; de Vries IJM
Cancer Immunol Immunother; 2020 Mar; 69(3):477-488. PubMed ID: 31980913
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
[TBL] [Abstract][Full Text] [Related]
20. Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.
van Beek JJP; Flórez-Grau G; Gorris MAJ; Mathan TSM; Schreibelt G; Bol KF; Textor J; de Vries IJM
Cell Rep; 2020 Jan; 30(4):1027-1038.e4. PubMed ID: 31995747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
